Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
ASGCT 2025 showcases MeiraGTx’s ALS and pediatric obesity therapies and Rgenta’s RSwitch technology for Friedreich’s ataxia.
Neurodegenerative diseases like ALS, frontotemporal dementia, and Friedreich’s ataxia pose significant challenges with limited treatment options. ALS and frontotemporal dementia lead to motor neuron degeneration and cognitive decline, respectively. These diseases cause severe disability and reduced life expectancy. Friedreich’s ataxia results from frataxin (FXN) deficiency, leading to coordination loss, muscle weakness, and heart complications. Metabolic disorders, like pediatric obesity, increase risks of diabetes and cardiovascular disease, especially when lifestyle interventions fail.
At ASGCT 2025, innovative cell and gene therapies target these diseases. MeiraGTx’s AAV-hUPF1 therapy for ALS and frontotemporal dementia restores neuron health by correcting protein dysfunction. MeiraGTx’s BDNF-based hypothalamic gene therapy for pediatric obesity shows significant weight loss and metabolic improvements in preclinical models. Rgenta’s RSwitch technology offers precise control over FXN expression for Friedreich’s ataxia. It minimizes risks like cardiotoxicity through adjustable dosing via oral RDrugs.
Advancements in Neurodegenerative and Metabolic Diseases: MeiraGTx’s Gene Therapies for ALS and Pediatric Obesity
Building on these advancements in rare genetic disorders, the ASGCT meeting also showcases therapies tackling neurodegenerative and metabolic challenges, where gene therapies are showing remarkable potential.
MeiraGTx is presenting four posters at ASGCT 2025, focusing on gene therapies for amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and severe pediatric obesity. A standout study involves a gene therapy delivering brain-derived neurotrophic factor (BDNF) to the hypothalamus to treat obesity, showing significant weight loss and improved metabolic health in preclinical mouse models. This could be a game-changer for pediatric obesity, a condition with few effective treatments. Obesity, particularly in children, can lead to serious long-term health issues like diabetes and heart disease, so a targeted gene therapy offering a new approach could have a profound impact.
Another presentation highlights an optimized AAV-hUPF1 therapy for ALS and frontotemporal dementia, demonstrating strong preclinical efficacy. ALS is a progressive neurodegenerative disease that attacks motor neurons, leading to muscle weakness and paralysis, while frontotemporal dementia is characterized by early personality changes and cognitive decline. MeiraGTx’s therapy is aimed at addressing these challenging conditions by introducing a modified gene to restore the function of specific proteins involved in neuron health.
MeiraGTx is also advancing gene therapy safety and efficacy through novel promoter designs that enhance gene expression while reducing required doses. Promoters are essential for turning on genes in therapy, and improving them can increase the precision and effectiveness of treatments, potentially making them safer and more affordable.
Rgenta Therapeutics’ RSwitch for Friedreich’s Ataxia
Rgenta Therapeutics is showcasing its proprietary RSwitch technology, a regulatable gene therapy system that allows precise control of transgene expression using orally administered small molecules (RDrugs). This means that instead of a one-time, permanent change to the gene, RSwitch enables doctors to adjust the therapy’s effects in response to the patient’s needs. At ASGCT 2025, Rgenta will present data showing RSwitch’s ability to fine-tune frataxin (FXN) expression for Friedreich’s ataxia (FA), a progressive neurodegenerative disease caused by FXN deficiency. FA is characterized by the gradual loss of coordination, muscle weakness, and heart problems, often leading to early death. The gene therapy approach aims to correct the FXN deficiency, but unregulated FXN overexpression can lead to harmful side effects, including cardiotoxicity (damage to the heart).
However, RSwitch technology enables dose-dependent control, meaning doctors can carefully manage how much FXN is produced. In mouse models, this technology has achieved human-like FXN levels with minimal doses of RDrugs, showing that it can be controlled safely and effectively. The technology also demonstrated transgene regulation in neurons, which are the cells responsible for sending signals throughout the body, further underscoring its potential for treating neurological disorders. Rgenta’s CEO, Simon Xi, emphasized that RSwitch could significantly improve the safety and efficacy of gene therapies, making it a promising tool for tackling diseases like FA. The system also has the potential to attract partnerships with other companies, which could speed up the development of treatments for various genetic and neurological diseases.
Broader Innovations in Gene Therapy for Disease Management
Beyond MeiraGTx and Rgenta, ASGCT 2025 highlights a range of gene therapy advancements tackling neurodegenerative and metabolic diseases. Researchers are exploring adeno-associated viral (AAV) vectors with enhanced tissue specificity to improve delivery to the brain and spinal cord for neurodegenerative conditions. Novel capsid designs and delivery methods, such as intrathecal administration, are being developed to cross the blood-brain barrier more effectively, a critical challenge in treating diseases like ALS. For metabolic disorders, gene therapies targeting liver and adipose tissue are showing promise in regulating insulin sensitivity and lipid metabolism, offering potential solutions for obesity-related complications. Additionally, RNA-based therapies and CRISPR-based editing are emerging as complementary approaches, enabling precise genetic corrections or temporary gene modulation. These advancements, combined with improved safety profiles through innovations like MeiraGTx’s optimized promoters and Rgenta’s regulatable systems, move innovation in the direction of more effective and personalized treatments across these complex disease areas.
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
The iPSC & Small Molecule Convergence: Redefining What’s Possible in CNS Drug Development
2025-08-07
After Deaths and a Pause, Sarepta Restarts ELEVIDYS Shipments After FDA Review Eases Safety Concerns
2025-07-29
US BIO 2025 to Unite 20,000+ Global Biotech Leaders in Boston for Innovation, Policy, and Investment Collaboration
2025-06-12
